Trillium Therapeutics Inc.
Records under this name other than the patents Trillium Therapeutics Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Trillium Therapeutics Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,354,109 | Multimeric Fc receptor polypeptides Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,969,789 | Treatment of CD47+ Disease Cells with SIRP Alpha-FC Fusions Formerly held In force · High confidence | In force | High confidence | |
| US 10,906,954 | Treatment of CD47+ Disease Cells with SIRP Alpha-FC Fusions Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,446,315 | Enhancement of CD47 Blockade Therapy by Proteasome Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 11,779,631 | Improvements in CD47 Blockade Therapy by Hdac Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 11,771,764 | CD47 Blockade with Radiation Therapy Formerly held In force · High confidence | In force | High confidence | |
| US 12,178,803 | CD47 Blockade with Parp Inhibition for Disease Treatment Formerly held In force · High confidence | In force | High confidence | |
| US 8,729,247 | Multimeric Fc receptor polypeptides Formerly held Lapsed on the fee record Ended May 20, 2026 · USPTO record | Lapsed on the fee record | Ended May 20, 2026 | USPTO record |
| US 10,696,670 | Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins Lapsed on the fee record Ended Jun 30, 2024 · USPTO record | Lapsed on the fee record | Ended Jun 30, 2024 | USPTO record |
| US 7,632,495 | Use of soluble fgl2 as an immunosuppressant Formerly held Term ended Term ended Apr 15, 2024 · USPTO record | Term ended | Term ended Apr 15, 2024 | USPTO record |